

THE CAMPBELL FOUNDATION

GRANT HISTORY

1995-Present

Scroll down within document to read



| YEAR | AMOUNT | GRANT RECIPIENT | GRANT TITLE |
|------|----------|---|---|
| 2021 | \$80,000 | The Wistar Institute | “Role of Intestinal Barrier Integrity and Antibody Glycosylation in Long-COVID During HIV-infection” |
| 2021 | \$85,000 | HIV-Assist | Improving precision HIV care through a mobile device application for evidence-based decision and education support for antiretroviral selection |
| 2021 | \$90,000 | Weill Cornell Medicine Clinical Directors Network | Investigating the Predictive Role of the Neutrophil-to-Lymphocyte Ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) for Measures of Cardiovascular Disease and Neurologic Outcomes in People Living with HIV-1 |
| 2020 | \$80,00 | University of Miami Miller School | Anti-HIV Antibodies for Effective & durable Adeno-Associated Virus (AAV) Delivery |
| 2020 | \$85,000 | Burnet Institute | Enhancing the Vaginal Environment and Microbiota (EVE-M) to Prevent HIV Transmission |
| 2020 | \$80,000 | Tel Aviv University | Using the Germline Precursors of the Anti-HIV Broadly Neutralizing Antibody BG18 as a Template for HIV Vaccine Design |
| 2018 | \$75,000 | McGovern Medical School at UTHealth | Mechanisms of Fibrosis in Chronic Treated HIV Infection |
| 2018 | \$88,000 | Tufts University School of Medicine | Linking Structural Dynamics of HIV-1 Env to Correlates of Immunoprotection in the RV144 Vaccine Trial |

| | | | |
|------|-----------|---|---|
| 2018 | \$75,000 | Stanford University School of Medicine | A Combined Drug Resistance and Virus Load Point of Care Assay |
| 2018 | \$100,000 | The Wistar Institute | Role of Host Glycosylation in the Galectin-9-Mediated Reversal of HIV Latency |
| 2017 | \$80,000 | The Ohio State University College of Medicine | Grant to Develop Gene Editing Tool to Destroy Latent HIV Cells in Lymph Nodes |
| 2017 | \$10,000 | The Montrose Center | Hurricane Harvey Emergency Grant |
| 2017 | \$10,000 | AIDS Foundation Houston | Hurricane Harvey Emergency Grant |
| 2017 | \$75,000 | David Geffen School of Medicine at UCLA | Novel Therapies for HIV-Related Aging of the Immune System |
| 2017 | \$25,000 | Miami Center for AIDS Research University of Miami Miller School of Medicine | Local Research Grant Initiative |
| 2017 | \$25,000 | Broward Health Comprehensive Care Center | Local Research Grant Initiative |
| 2017 | \$25,000 | Herbert Wertheim College of Medicine at FIU | Local Research Grant Initiative |
| 2017 | \$85,000 | Indiana University School of Medicine | Probenecid-Boosted Tenofovir: A New Strategy for On-Demand HIV Pre-Exposure Prophylaxis |
| 2016 | \$77,495 | Massachusetts General Hospital | Brain inflammation and cognitive decline in HIV patients with dysbiotic microbiome |
| 2016 | \$79,151 | Scripps Research Institute, Jupiter, FL | Targeting HIV-1 Latent Infection with a Potent Tat Inhibitor |

| | | | |
|------|-----------|---|---|
| 2016 | \$80,000 | Northwestern University | Controlling HIV Release from Cells with First-in-Class Drugs Targeting Virus Budding |
| 2016 | \$75,000 | Drexel University College of Medicine | Long-Acting Formulation for the Systemic Delivery of HIV-1 Inactivators Using Metamorphic T-Cell-like Liposomes |
| 2015 | \$60,000 | Columbia University Medical Center | Arterial Wall Infection by HIV as a Trigger for Arterial Wall Inflammation |
| 2015 | \$48,900 | Case Western/Rainbow Babies Hospital | Use of EndoPAT for Measurements of Endothelial Dysfunction in HIV-infected Children and Healthy Controls |
| 2015 | \$30,000 | Children's Diagnostic & Treatment Center | Local Research Grant Initiative |
| 2015 | \$30,000 | University of Miami Miller School of Medicine | Local Research Grant Initiative |
| 2015 | \$30,000 | Florida Atlantic University Charles Schmidt College of Medicine | Local Research Grant Initiative |
| 2015 | \$100,000 | Ben-Gurion University, Israel | Efficacy of Tenofovir Delivered to the Brain by Novel Nanovesicles in a Neuro-HIV Mouse Model |
| 2014 | \$50,000 | amfAR | Countdown to a Cure Matching Grant Program |
| 2014 | \$85,000 | Children's Hospital Boston at Harvard | Novel Mechanisms Regulating HIV-1 Latency in HIV/TB Co-Infection |
| 2014 | \$79,375 | The George Washington University | Defining the Unique Biomarkers of Latently Infected T-Cells |
| 2014 | \$88,415 | Johns Hopkins University Medical School | Pharmacokinetics and Pharmacodynamics of the Etonogestrel Implant When Co-administered With Efavirenz |
| 2014 | \$79,954 | VA Medical Center, Vermont | Blocking CXCL9 to Improve Anti-HIV Potency of Tenofovir |
| 2013 | \$100,000 | Mount Sinai School of Medicine | Simultaneous Disruption of Latency & Immune Enhancement by Poly ICLC During HIV-1 Infection |
| 2013 | \$88,000 | Univ. of Pittsburgh | MicroRNAs as Biomarkers for HIV-1 Associated Neurocognitive Impairment & |

| | | | |
|------|-----------|----------------------------------|---|
| | | | Dementia: Development of a Sensitive Diagnostic Tool |
| 2013 | \$50,000 | R.A.I.N., Oklahoma City | Emergency Relief Grant |
| 2013 | \$86,431 | Univ. of California, Davis | Pre-Selective Anti-HIV Vectors for Improved HIV Stem Cell Gene Therapy |
| 2012 | \$73,047 | Washington University | Topical Fusogenic Nanosnares for HIV Prophylaxis |
| 2012 | \$82,500 | UCSF | Restriction of HIV Replication |
| 2012 | \$100,000 | Mount Sinai School of Medicine | Isolation of Novel Prothymosin-a Variants with Potent Anti-HIV & Interferon Inducing Activities |
| 2012 | \$86,130 | Ben-Gurion University | Delivery of Tenofovir to the Brain by Novel Nanovesicles for the Treatment of Neuro-HIV |
| 2012 | \$78,479 | University of Minnesota | Investigation of a Novel Chemotherapy to Target HIV Infectivity |
| 2011 | \$32,919 | Univ. of Miami | Host Apolipoprotein E Affects Development of HIV-Ass'd Neurological Disease |
| 2011 | \$25,000 | AIDS Alabama | Emergency Relief Grant |
| 2011 | \$60,000 | Pennsylvania State University | Alternative Therapies to Combat HIV: Targeting Tat by Natural Products |
| 2011 | \$77,000 | UC Davis | Role of the MSS1 Protein in HIV-1/SIV Replication & Pathogenesis |
| 2011 | \$85,000 | UCLA | Telmisartan and Flow-Mediated Dilatation in Older HIV+ Patients at Risk for Cardio Disease |
| 2011 | \$20,000 | UCLA | Assessing Cardio Risk & Impact of Hep C Treatment on Cardio Risk Biomarkers |
| 2011 | \$50,000 | AMFAR | ARCHE Program Grant |
| 2010 | \$55,000 | Washington University, St. Louis | Dipeptidyl Peptidase-4 Inhibition & Immune Function in HIV |
| 2010 | \$44,000 | Univ. of Southern California | Identification of Novel Cellular Cofactors of HIV |

| | | | |
|------|-----------|------------------------------------|---|
| 2010 | \$70,000 | Univ. of Vermont | Targeting Human Proteins for Treatment of Cryptosporidiosis |
| 2010 | \$28,435 | Dartmouth-Hitchcock Medical Center | Semen Protects Target CD4+ Cells from HIV Infection |
| 2010 | \$51,953 | UC Davis | Flash-Heating Breast Milk to Decrease Morbidity, Improve Growth, & Reduce HIV Transmission in HIV-Exposed Infants |
| 2010 | \$64,327 | Rush Univ. Medical Center | Acupuncture to Reduce HIV-Associated Inflammation |
| 2010 | \$71,815 | UC San Diego | Prosp. Study of Vitamin D on Cutaneous Innate Immune Responses in HIV+ Subjects w/ and w/out CA-MRSA |
| 2009 | \$40,000 | Burnet Institute, Australia | Adaptive Changes in HIV Subtype C Envelope Glycoproteins Contributing to Pathogenicity |
| 2009 | \$45,047 | Brigham & Women's Hospital | Detection of Minority HIV-1 Variants by Deep Sequencing |
| 2009 | \$35,000 | Univ. of Minnesota | Enabling Lethal Restriction of HIV-1 by Human APOBEC3G |
| 2009 | \$88,000 | Univ. of California, San Francisco | Importance of Plasmacytoid Dendritic Cells in HIV Infection |
| 2008 | \$96,381 | New York Blood Center | Developing Cell Penetrating Peptides as HIV-1 Assembly Inhibitors |
| 2008 | \$33,500 | Emory University | Mechanisms of Antiviral Activity of TRIM-5 Alpha Protein |
| 2008 | \$105,039 | Population Council | A Novel DARPins Strategy for Combating HIV |
| 2008 | \$43,054 | Imperial College London | Gene Expression Microarray Analysis of NK Cell Function in the Gastro. Tract of HIV+ People |
| 2007 | \$65,700 | University of Minnesota | Impact of Human APOBEC3 Proteins on HIV Drug Resistance |
| 2007 | \$80,000 | University at Buffalo | Novel Assays for Antiretroviral Intra/Extracellular Measurements |

| | | | |
|------|-----------|--|---|
| 2007 | \$81,000 | Roger Williams Medical Center | Enhancing Potency of Anti-HIV Chimeric Immune Receptors |
| 2007 | \$79,640 | Beth Israel Deaconess Med Ctr | Preclinical Evaluation of Bacterially-Dis-played Anti-HIV Antibodies to Prevent HIV Infection |
| 2007 | \$65,128 | UCLA Medical Center | Assessment of Drug-Resistance Mutation Fitness Costs Across HIV-1 Clades |
| 2007 | \$88,000 | Washington University | HIV PI-Induced Insulin Resistance: Role of SOCS-1 |
| 2007 | \$59,246 | Tufts University School of Medicine | Postprandial Endothelial Dysfunction After a High-Fat Meal in HIV+ Patients |
| 2007 | \$71,973 | Univ. of Massachusetts | Molecular & Biologic Properties of Transmitted HIV-1 Variants in a Mother-Child Cohort |
| 2006 | \$104,181 | Albany Medical College | Mechanisms of Naturally-Occurring HIV-1 Inhibitors |
| 2006 | \$84,018 | Univ. of Colorado Health Sciences Center | Alpha-1 Antitrypsin Inhibits HIV-1 (Extension funding) |
| 2006 | \$97,196 | Cleveland Clinic | Analysis of Novel Mutagenic Compounds to Lead HIV to Error Catastrophe |
| 2006 | \$88,000 | Univ. of Southern California | Design of Second Generation HIV-1 Integrase Inhibitors |
| 2006 | \$90,273 | Univ. of California, Davis | Long-term Non-Progressor Resistance Factors |
| 2006 | \$79,200 | Thomas Jefferson University | Role of Heterologous Hep C Virus RNA-Dependent RNA Polymerase in Human Cells...Enhancing RNAi Against HIV-1 |
| 2006 | \$85,800 | Medical College of Wisconsin | HIV Hiding in Mature Dendritic Cells Establish Viral Reservoirs |
| 2005 | \$83,981 | Rush University Medical Center | Evaluating the Role of Antigen-Specific Tcells in HIV Immunity |
| 2005 | \$87,718 | George Washington University | Mechanisms of Atherogenic Effect of HIV-1 Infection |
| 2005 | \$11,603 | Yale University School of Medicine | CXCR4 Allosteric Agonists |

| | | | |
|------|-----------|---|---|
| 2005 | \$82,098 | Wistar Institute | Mouse Model to Test Efficacy of HIV-1 Vaccines |
| 2005 | \$110,000 | UMASS Medical School | Mechanism of HIV-1 Persistence in the Face of HAART |
| 2005 | \$160,000 | CRI, New England | Randomized Controlled Trial of a Weekly Schedule of Five Days On / Two Days Off |
| 2004 | \$75,000 | University of Colorado Health Sciences Center | Alpha-1 Antitrypsin Inhibits HIV-1 |
| 2004 | \$60,000 | University of Pittsburgh | Evaluation of Novel Antiviral Targeting HIV-1 Vpr |
| 2004 | \$40,000 | Univ. of California, San Diego | Protecting Cells from HIV Infection & Destruction In Vivo |
| 2004 | \$78,650 | Burnet Institute, Australia | Role of HIV Infection of Astrocytes in the Development of HIV-Ass'd Dementia |
| 2004 | \$65,100 | Johns Hopkins | Targeting the HIV Macrophage Reservoir |
| 2004 | \$75,000 | Aaron Diamond AIDS Research Ctr. | Inhibition of Integrase-Mediated Viral Nuclear Transport |
| 2004 | \$80,000 | Mount Sinai School of Medicine | Chemical Inhibitors for the HIV Tat/PCAF Complex |
| 2003 | \$44,000 | Ohio State University | Impact of Anti-AIDS Drugs & Drug Resistance on HIV Evolution |
| 2003 | \$79,200 | Mass. General Hospital | HIV-1/HCV Coinfection: Role of HCV-Specific Tcells in Complicating HIV-1 Infection & Therapy |
| 2003 | \$71,500 | Mass. General Hospital | Comprehensive Assessment of HIV-1 Specific CTL Responses in Infected Chinese for Vaccine Design |
| 2003 | \$75,000 | Global Alliance to Immunize Against AIDS (GAIA) | GAIA AIDS Vaccine Project/Bamako, Mali |
| 2003 | \$60,000 | University of Southern California | HIV Vaccine Development Utilizing a Goat Lentivirus |
| 2003 | \$25,017 | The New York Blood Center | HIV-1 Entry Inhibitors Targeting Hydrophobic Cavity in gp120 |

| | | | |
|------|-----------|---|--|
| 2003 | \$88,062 | University of Miami | Longitudinal Assessment of Autologous Neutralizing Antibodies in Children Perinatally Infected w/HIV-1 |
| 2003 | \$38,500 | University of Southern California | Epidemiology & Clinical Significance of PCP Colonization |
| 2003 | \$75,000 | University of California, San Francisco | Identification of the CD8+ Cell Anti-HIV Factor |
| 2002 | \$55,000 | Univ. of Massachusetts | Determinants of Non-Progressive HIV-1 Infection in Women & Children |
| 2002 | \$75,843 | Center for Blood Research | Subtype-Specific Regulation of HIV1 Gene Expression |
| 2002 | \$65,000 | Rush-Presbyterian-St. Luke's Medical Center | Impact of IL-7 on HIV Infection of Naive Cells...Potential Role of IL-7 as an Immune Modulator |
| 2002 | \$96,525 | CRI, New England | Maintenance HIV Suppression w/Cyclic Weekly HAART 5/2 Schedule |
| 2002 | \$103,202 | Childrens Hospital Los Angeles | Bone Size & Bone Mineral Density in HIV+ Children & Adolescents |
| 2002 | \$83,113 | Washington University | Extension Grant from 2001 (see above) |
| 2002 | \$32,141 | New Jersey Med. School | Prevalence of Anal HPV & Anal Dysplasia in HIV Seropositive Adolescent & Young Adult Males |
| 2002 | \$79,200 | Dana-Farber Cancer Inst. | Viral Determinants & Mechanisms for HIV-1 Neurotropism & CNS Pathogenesis |
| 2001 | \$72,050 | Cornell University | Role of CCR-5 in Interlukin-12 Production in HIV-1 Infection |
| 2001 | \$79,200 | St. Luke's-Roosevelt Hospital Center | Application of Molecular Techniques to the Study of HIV-Associated Lipodystrophy |
| 2001 | \$58,267 | Georgetown University | Development of HHV-6 U94 As a Novel Anti-HIV Therapy |
| 2001 | \$87,467 | Washington Univ. School of Medicine | Rosiglitazone & Exercise Training: Effects on HIV+ People w/Insulin Resistance, Hypertriglyceridemia, & Adipose Tissue Maldistribution |

| | | | |
|------|-----------|------------------------------------|---|
| 2001 | \$77,000 | Univ. of California, San Diego | Lentiviral Vectors Interfering w/CD4 Downmodulation as an HIV Anti-viral Strategy |
| 2001 | \$55,000 | Univ. of California, San Francisco | Systemic Delivery of Tat and the Effects on HIV Replication and the Host |
| 2001 | \$10,000 | Childrens Hope Foundation | Emergency Grant (9/11 Impact) |
| 2001 | \$50,000 | Aaron Diamond AIDS Research Center | Aggressive Antiviral Therapy During Acute HIV-1 Infection |
| 2001 | \$50,072 | Schneider Childrens Hospital | Siberian Ginseng: A Modulator of TH1-Like T-cell Cytokine mRNA & Cytokine Protein Expression in Pediatric HIV Infection |
| 2000 | \$25,000 | The Wistar Institute | Extension Grant from 1998 (see above) |
| 2000 | \$47,850 | University of Kentucky | Analysis of Antiviral Efficacy of RRI |
| 2000 | \$64,990 | UCLA School of Medicine | Phase I Gene Therapy Study Using a Lentiviral Vector for Patients w/Multi-Drug Resistance to HIV |
| 2000 | \$91,707 | Washington University | Characterizing Osteopenia in HIV+ People Treated w/ Protease Inhibitors |
| 2000 | \$55,000 | Robert Wood Johnson Medical School | Extension Grant from 1999 (see above) |
| 2000 | \$63,000 | UCLA School of Dentistry | Role of Candida Species in Endodontic Infections in HIV+/AIDS Population & Its Effect on Endo. Treatment |
| 2000 | \$26,675 | University Hospitals of Cleveland | Pilot Trial to Evaluate Effect of Antioxidants in HIV+ Patients w/Lipodystrophy or Hyperlactatemia |
| 2000 | \$45,000 | State University of New York | Generation of Anti-HIV Cytotoxic T-Lymphocytes Using Lentivirus Vectors |
| 1999 | \$105,686 | University of Southern Cal. | Extension Grant from 1998 (see above) |
| 1999 | \$69,832 | The Rockefeller University | Importance of Dendritic Cells in SIV delta nef Vaccines |
| 1999 | \$53,381 | St. Louis University | Enhancement of Anti-HIV Immunity by Sequential Immunization w/Heterologous Live Virus Vectors |

| | | | |
|------|-----------|--|--|
| 1999 | \$85,121 | Washington University | Characterizing Diabetes & Lipid Disorders in HIV+ People Treated with Protease Inhibitors |
| 1999 | \$60,500 | Rush-Presbyterian-St. Luke's Med. Center | Mechanism(s) of Protection Against in utero HIV Transmission |
| 1999 | \$50,000 | Robert Wood Johnson Medical School | Development of a Tat-Antagonist Therapeutic for AIDS |
| 1999 | \$74,970 | Mass. General Hospital | Artificial Thymus for HIV-Induced Immunodeficiency |
| 1999 | \$30,000 | Tampa Bay Research Inst. | Extension Grant from 1998 (see above) |
| 1999 | \$41,363 | City of Hope, CA | Extension Grant from 1997 (see above) |
| 1999 | \$38,500 | Columbia University | Silencing Harmful Genes to Prevent Disease |
| 1998 | \$65,093 | Oregon Health Sciences University | Preclinical Evaluation of Anti-HIV Lipophilic Prodrugs |
| 1998 | \$58,270 | Tampa Bay Research Institute | Effects of Pinecone Extract (PC6) on the Progression of Murine AIDS |
| 1998 | \$71,500 | Pediatric AIDS Foundation | Pediatric CTL Responses and HIV Disease Progression |
| 1998 | \$70,590 | Body Positive, Houston | Use of Anabolic Steroids, Optimum Nutrition, and Exercise Therapy for HIV+ Adult Male Patients |
| 1998 | \$65,000 | CRIA, New York | Pilot Study of the Effect of Recombinant Human Growth Hormone (Serostim) in the Treatment of Truncal Obesity Associated with HIV |
| 1998 | \$75,000 | INSERM, France | Extension Grant from 1997 (see above) |
| 1998 | \$100,000 | The Wistar Institute | Immune Function and Anti-HIV Resistance Following HAART |
| 1998 | \$42,287 | University of Kentucky | Cloning of HIV-1 Genes in Tissue Culture for Drug Screening & Engineering of Therapeutic Antibodies Against HIV-1 Tat Protein |
| 1998 | \$8,928 | University of Southern Cal. | Extension Grant from 1997 (see above) |
| 1998 | \$74,439 | UCLA School of Medicine | Factors Related to Appointment & Medication Non-Adherence in HIV+ Men and Women |

| | | | |
|------|-----------|--|---|
| 1997 | \$40,645 | University of Kentucky | Effect of Folinic Acid on the Hematological Toxicity of Selected Medications Used in the Treatment of Chronic HIV |
| 1997 | \$78,969 | University of Miami | Evaluation of CD8 Immunologic Recovery After Subcutaneous IL2 Administration |
| 1997 | \$45,000 | Community Research Initiative, New England | CD-4 Levels That Have Risen as a Result of Initiation of Protease Inhibitor Therapy |
| 1997 | \$50,500 | Community Research Initiative, Miami | Joint Study with CRI New England |
| 1997 | \$44,900 | Montrose Clinic, Houston | Clinical Director for HIV Research Staff Position |
| 1997 | \$26,000 | AIDS Project of the Ozarks | Provide Clinical Trial Access to HIV+ Patients in SW Missouri |
| 1997 | \$114,615 | University of Southern California | Immune Responses to HIV in Humans Infected with a Novel Virus |
| 1997 | \$39,772 | City of Hope, CA | Anti-HIV Activity in Herbs: A Molecular Characterization |
| 1997 | \$75,000 | INSERM, France | Study of Non-Progressor HIV Patients |
| 1996 | \$8,560 | Mercy Hospital, Miami | Clinical Trial of Cats Claw in Asymptomatic HIV+ Subjects |
| 1996 | \$27,500 | Oregon Health Sciences University | Extension of 1995 Grant (see above) |
| 1996 | \$24,000 | University of Miami | Efficacy of Pentoxifylline in the Treatment of Pruritic Papular Eruption of HIV+ Patients |
| 1995 | \$30,000 | University of Miami | Treatment of Scabies with Ivermectin |
| 1995 | \$29,759 | Oregon Health Sciences University | Combined Modality Approaches to Treat Retroviral Disease |
| 1995 | \$15,510 | Mercy Hospital, Miami | Clinical Trial of Thalidomide in the Treatment of HIV-Associated KS |